The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Another popped up 1.5m in total. Hope so
17-Jun-21 13:15:07 30.00 253,033 Unknown* 29.50 30.50 75.91k O
17-Jun-21 13:15:07 30.00 253,033 Unknown* 29.50 30.50 75.91k O
17-Jun-21 12:47:59 30.00 493,935 Unknown* 29.50 30.50 148.18k O
17-Jun-21 12:47:52 30.00 506,065 Unknown* 29.50 30.50 151.82k O
I suspect it's being sold into massively, placing shares taking a profit, traders and some just exiting after averaging down and minimising losses. Just needs time to churn...agree, next year should be a much different place.
@PG From what I understand what is good for IBS-C is bad for IBS-D and vice versa for obvious reasons. So a correct diagnosis is vital or could make the situation worse. A lot of patients show both symptoms and therefor can't be diagnosed correctly or can't be prescribed anything.
So an effective single product that covers all, means a doctor only needs to diagnose IBS and not worry about C or D.
That's my understanding of it. Not a medical profession either.
My point is more for a HTO situation where Vlad is not a willing participant. Pre-clinical or even early clinical stage no company is going to touch them unless Vlad is a willing participant. How much of the IP is in his head, how much of the IP is currently protected??
Absolutely he could set-up HEMO2 and work from what he knows, yes it would be a set back but would just needs to make it a little better than what he sold and he would be good. I am not saying that is what would happen, just why a TO won't if Vlad doesn't want it, Veto or not.
Can't see a TO here unless Vlad wants it. What is to stop Vlad and co leaving and starting HEMO2 with all the knowledge and skills they possess. Take Vlad and Co out of HEMO you have nothing.
If Vlad and co leave the company you just bought, what have you actually bought?
Circumstances and outlooks change as do the opinions with them. Why do people get nailed to the cross on an opinion they held from 6-12 months ago when HEMO look vastly different than it does now. No one knew the Lilly would be a no deal (for now) and lead us here with the CLN's.
As facts change so do opinions...get over it.
Can't see a HTO here. What is to stop Vlad and co leaving and starting HEMO2 with all the knowledge and skills they possess. Take Vlad and Co out of HEMO you have nothing also the Sandlers own too many Shares for a HTO to happen.
@Bo...10 to 15 is a stretch. If we're in clinical stage in 12 months success could be 5-6 years. If the boxes are ticked successfully along the way the majority of the value will be raised long before then. I don't intend to hold 100% of my holding until something is on the shelf I will skim as we go. I am well aware of the risks and the possibility of complete failure and I will reassess as I go. I see no less risk than when I invested a year ago. Everything still on track in my opinion. It will hurt but I can afford to lose it and if you hold your nerve and have patients that's how you get the big pay day as long as you backed the right horse. Only time will tell.
A successful product on the shelf will mean a mcap of a billion plus. Even if mint dilute the crap out of it to a billion shares that's still a £1+ plus share price minimum imo. I think Vlad thinks the same, get the product through trials and the SP will take care of its self . Product has to be the focus now business can come later. That's why I bought and I am prepared to wait years for that with a top slice along the way. Would be nice to get a top slice this year... who knows. Only thing that's changed is the share price.